Picture of Pathfinder Cell Therapy logo

PFND Pathfinder Cell Therapy Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Annual income statement for Pathfinder Cell Therapy, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

R2010
December 31st
2011
December 31st
C2012
December 31st
C2013
December 31st
2014
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue00.0730.1140.0540
Cost of Revenue
Gross Profit00.0470.0640.0170
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses1.2911.22.171.561.12
Operating Profit-1.29-11.2-2.06-1.51-1.12
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes-1.29-11.3-2.16-1.71-1.39
Provision for Income Taxes
Net Income After Taxes-1.29-11.3-2.16-1.71-1.39
Net Income Before Extraordinary Items
Net Income-1.29-11.3-2.16-1.71-1.39
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income-1.29-11.3-2.16-1.71-1.39
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.002-0.007-0.003-0.003-0.002
Dividends per Share